Everolimus
Quick Overview
| Attribute | Value |
|---|---|
| Drug Name | Everolimus |
| DrugBank ID | DB01590 |
| KG Predictions | 80 |
| DL Predictions (≥0.7) | 573 |
| Evidence Level | L5 |
| NPRA Status | Approved |
Sample Brand Names in Malaysia
Predicted Indications
This drug has 80 knowledge graph predictions and 573 high-confidence deep learning predictions.
Top KG Predictions
| Indication | Source |
|---|---|
| breast neoplasm | KG |
| renal cell adenocarcinoma | KG |
| clear cell renal carcinoma | KG |
| tuberous sclerosis | KG |
| situs inversus | KG |
| Marfan syndrome | KG |
| renal cell carcinoma (disease) | KG |
| kidney angiomyolipoma | KG |
| nonpapillary renal cell carcinoma | KG |
| breast carcinoma | KG |
FHIR Resources
Access drug data via FHIR R4 API:
- MedicationKnowledge:
/fhir/MedicationKnowledge/DB01590
Related Resources
| Resource | Link |
|---|---|
| DrugBank | View on DrugBank |
| PubMed | Search PubMed |
| ClinicalTrials.gov | Search Trials |
Disclaimer
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.